Duke logo

ATTAC-P (Glioblastoma, Glioma, Medulloblastoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if it is possible to create a study vaccine and to see if the study vaccine is safe for children who have glioma or medulloblastoma and adults who have medulloblastoma.

What is the Condition Being Studied?

Glioma or medulloblastoma (brain cancer)

Who Can Participate in the Study?

Children 18 years old or younger who have been newly diagnosed with glioma

OR

Children 3 to 18 years old and adults 19 to 35 years old who have been diagnosed with medulloblastoma that has returned.

Age Group
Adults, Children

What is Involved?

If you or your child choose to join this study, you or your child will:
- Have a leukapheresis procedure in which blood is collected into a machine that removes white blood cells and then returns the remainder of the blood back to you. The white blood cells removed from the blood are used to make a study vaccine.
- Have standard radiation therapy with or without chemotherapy before beginning study vaccine, if you are newly diagnosed with a brain tumor. Vaccines are given as a shot in the leg.

Study Details

Full Title
A Phase 1 Trial of CMV RNA-Pulsed Dendritic Cells with Tetanus-Diphtheria Toxoid Vaccine in Pediatric Patients and Young Adults with Glioblastoma or Recurrent High Grade Glioma (Glioblastoma, Medulloblastoma, or Grade III Glioma)
Principal Investigator
Neuro-oncologist
Protocol Number
IRB:PRO00092868
NCT:NCT03615404
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698